Pneumotoxicity of lipopolysaccharide in nitric oxide - Deficient rats is limited by a thromboxane synthase inhibitor

Journal of Physiology and Pharmacology

Volumn 48, Issue 4, 1997, Pages 645-653

  Wolkow P P ^a   Bartus J B ^a   Gryglewski, R J ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Lipopolysaccharide; Lung injury; Nitric oxide; Prostacyclin; Thromboxane

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CAMONAGREL; ICOSANOID; ILOPROST; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTACYCLIN; THROMBOXANE A2; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MIXTURE; ENZYME INACTIVATION; ESCHERICHIA COLI; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG INJURY; LUNG TOXICITY; MALE; NONHUMAN; RAT; SEPTIC SHOCK;

ANIMALS; BLOOD PRESSURE; EPOPROSTENOL; ESCHERICHIA COLI; INDANS; LIPOPOLYSACCHARIDES; LUNG DISEASES; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROARGININE; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 2642701713     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Bone RC. Gram-negative sepsis: a dilemma of modern medicine (see comments). Clin Microbiol Rev 1993; 6: 57-68.
2. Anonymous. Increase in National Hospital Discharge Survey rates for septicemia United States, 1979-1987. MMWR - Morbidity& Mortality Weekly Report 1990; XX 39: 31-34.
3. Brigham KL. Oxygen radicals an important mediator of sepsis and septic shock. Klin Wochenschr 1991; 69: 1004-1008.
4. Luderitz T, Brandenburg K, Seydel U et al. Structural and physicochemical requirements of endotoxins for the activation of arachidonic acid metabolism in mouse peritoneal macrophages in vitro. Eur J Biochem 1989; 179: 11-16.
5. Pinsky MR, Vincent JL, Deviere J et al. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-575.
6. Creasey AA, Chang AC, Feigen L et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2856.
7. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-941.
8. Dhainaut JF, Vincent JL, Richard C et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23: 1461-1469.
9. Fisher CJ, Jr., Dhainaut JF, Opal SM et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group (see comments). JAMA 1994; 271: 1836-1843.
10. Fischer E, Marano MA, Van Zee KJ et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89: 1551-1557.
11. Pixley RA, De La Cadena R, Page JD et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993; 91: 61-68.
12. Kilbourn RG, Jubran A, Gross SS et al. Reversal of endotoxin-mediated shock by NG-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990; 172: 1132-1138.
13. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 1990; 182: 591-595.
14. Julou-Schaeffer G, Gray GA, Fleming I, Schott C et al. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990; 259: H1038-1043.
15. Nava E, Palmer RM, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? [see comments]. Lancet 1991; 338: 1555-1557.
16. Hutcheson IR, Whittle BJ, Boughton-Smith NK. Role of nitric oxide in maintaining vascular integrity in endotoxin-induced acute intestinal damage in the rat. Br J Pharmacol 1990; 101: 815-820.
17. Gryglewski RJ, Wolkow PP, Uracz W et al. Protective role of pulmonary nitric oxide in acute phase of endotoxemia in rats. 1997; in press
18. 2) in circulation. Acta Biol Med German 1978; 37: 715-723.
19. Cook JA, Wise WC, Halushka PV. Elevated thromboxane levels in the rat during endotoxic shock: protective effects of imidazole, 13-azaprostanoic acid, or essential fatty acid deficiency. J Clin Invest 1980; 65: 227-230.
20. 2 mediates hemodynamic and respiratory dysfunction in graded bacteremia (published erratum appears in Surgery 1989 Jun; 105(6): 810-1). Surgery 1986; 100: 214-221.
21. Kuhl PG, Bolds JM, Loyd JE et al. Thromboxane receptor-mediated bronchial and hemodynamic responses in ovine endotoxemia. Am J Physiol 1988; 254: R310-319.
22. Redl G, Abdi S, Traber LD et al. Inhibition of thromboxane synthesis reduces endotoxin-induced right ventricular failure in sheep. Crit Care Med 1991; 19: 1294-1302.
23. 2 synthesis in experimental septic shock. Circ Shock 1988; 26: 27-40.
24. Cook JA, Wise WC, Butler RR et al. The potential role of thromboxane and prostacyclin in endotoxic and septic shock. Am J Emerg Med 1984; 2: 28-37.
25. Jesmok G, Gundel R. Thromboxane-blocked swine as an experimental model of severe intravascular inflammation and septic shock. Shock 1995; 4: 379-383.
26. Furman BL, McKechnie K, Parratt JR. Failure of drugs that selectively inhibit thromboxane synthesis to modify endotoxin shock in conscious rats. Brit J Pharmacol 1984; 82: 289-294.
27. Seeger W, Walter H, Suttorp N et al. Thromboxane-mediated hypertension and vascular leakage evoked by low doses of Escherichia coli hemolysin in rabbit lungs. J Clin Invest 1989; 84: 220-227.
28. Slotman GJ, Quinn JV, Burchard KW et al. Thromboxane, prostacyclin, and the hemodynamic effects of graded bacteremic shock. Circ Shock 1985; 16: 395-404.
29. Salvemini D, Korbut R, Anggard E et al. Immediate release of a nitric oxide-like factor from bovine aortic endothelial cells by Escherichia coli lipopolysaccharide (published erratum appears in Proc Natl Acad Sci U S A 1990 Aug; 87(15): 6007. Proc Nat Acad Sci USA 1990; 87: 2593-2597.
30. Baydoun AR, Foale RD, Mann GE. Bacterial endotoxin rapidly stimulates prolonged endothelium-dependent vasodilatation in the rat isolated perfused heart. Brit J Pharmacol 1993; 109: 987-991.
31. Gryglewski RJ, Szczeklik A, Korbut R et al. The mechanism of anti-thrombotic, thrombolytic and fibrinolytic actions of camonagrel a new thromboxane synthase inhibitor. Wien Klin Wochenscht 1995; 107: 283-289.
32. Korbut R, Gryglewski RJ. The effect of prostacyclin and nitric oxide on deformability of red blood cells in septic shock in rats. J Physiol Pharmacol 1996; 47: 591-599.
33. Camporesi EM, Oda S, Fracica PJ et al. Eicosanoids and the hemodynamic course of live Escherichia coli-induced sepsis in baboons. Circ Shock 1989; 29: 229-244.
34. 2 increase in rats with peritonitis due to cecal ligation. Circ Shock 1985; 16: 297-305.
35. 2-receptor blockade and prostacyclin in porcine Escherichia coli shock. Arch Surg 1989; 124: 669-672.
36. Snapper JR, Hutchison AA, Ogletree ML et al. Effects of cyclooxygenase inhibitors on the alterations in lung mechanics caused by endotoxemia in the unanesthetized sheep. J Clin Invest 1983; 72: 63-76.